The Prostate Cancer Blog for Wives and Partners lets you know when new information has been added to our site. Anytime a new page is created — or we feel there is something worth noting — it will be posted here.
Daily pomegranate extract (8 ounces of liquid extract per day) did not significantly prolong PSA doubling time compared to juice or placebo in a new study (Pantuck et al) of men being treated for prostate cancer, which was published in the July 14 online edition of Prostate Cancer and Prostatic Diseases. In this study, 102 men who had a rising PSA received pomegranate extract, 17 men drank juice, and 64 men received placebo. The majority of men underwent prior surgery or radiation therapy and had prostate cancer initially staged as T2c or less. The median PSA doubling time increased by 4.5 months in the placebo group (11.1 to 15.6 months). Doubling time increased by 1.6 months in the pomegranate extract group (from 12.9 months to 14.5 months). In the juice group, PSA doubling time increased by 7.6 months (12.7 to 20.3 months). But none of the changes between the three groups were significantly significant. August 17, 2015.
Higher radiation doses are only beneficial for men with medium- and high-risk prostate cancer, according to a new study (Kalbasi et al) from researchers at Penn Medicine, which was published in the July 16th online edition of JAMA. When researchers compared overall survival from medical records of 12,229 men with low-risk prostate cancer to 16,714 men with intermediate-risk prostate cancer, and 13,538 men with high-risk prostate cancer, they determined that there was no survival benefit for men in the low-risk group. For every incremental increase of about 2 Gy in radiation dose, there was a 7.8% and 6.3% reduction in the hazard of death in for intermediate and high-risk men with prostate cancer respectively. July 30, 2015.
Six biomarkers that were used together predicted aggressive prostate cancer in men of color, according to a study (Yamoah et al) that was published in the July 20th online edition of the Journal of Clinical Oncology. Researchers looked at 20 biomarkers in 154 African American men and 243 European American men from four different medical centers who underwent a radical prostatectomy and had lymph nodes removed. They identified 6 biomarkers (ERG, AMACR, SPINK1, NKX3-1, GOLM1 and an androgen receptor) that showed statistically significant differential expression between the two groups of men. African American men are at higher risk of developing prostate cancer. July 25, 2015.
The American Cancer Society advocates a diet high in fruits and vegetables and low in saturated fat (think turkey vs steak) to help prevent prostate cancer. Now researchers in New Zealand suggest that a Mediterranean-type diet may help men who have prostate cancer. In this very small study (Erdrich et al), 20 men with prostate cancer, who were not receiving treatment and were under age 75 (Gleason score 6-7 [3+3 or 3+4]) ate a diet for 3 months that was rich in extra virgin olive oil (233 mg/kg per month), fresh frozen salmon (200 grams per week), unsweetened pomegranate juice (1 liter per week), canned legumes, and 2 cups of green tea a day. They also ate whole grains and substituted chicken for red meat. Researchers evaluated PSA level, C-reactive protein, and DNA damage at baseline and again after 3 months. Reductions in DNA damage were noted (DNA damage as been associated with prostate cancer risk). But there were no statistically significant relationships between the diet and C-reactive protein or PSA. July 23, 2015.
We’ve known for decades that smoking of any form isn’t healthy, but now cigarette smoking has been associated with twice the risk of prostate cancer recurrence in a retrospective study of 6,538 men (2,238 had never smoked, 2086 were former smokers, and 2214 were current smokers) who had radical prostatectomy, according to researchers at the Medical University of Vienna. Even ex-smokers had this higher risk, but researchers said the effects were mitigated in men who had quit for 10 years or longer. None of the men received other treatments before surgery, such as radiation, hormone treatment, or chemotherapy. Their cancer also had not metastasized (spread) when they were first diagnosed. Results of the study (Rieken et al) appeared online in the June issue of European Urology. June 23, 2015.
Chemotherapy may be an earlier option for men with high-risk, localized prostate cancer, according to research that was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. There have been several trials (CHAARTED, STAMPEDE, and the recent RTOG 0521) that have led researchers to suggest that using docetaxel may have greater benefit if it is used earlier in men with non-metastatic prostate cancer that is potentially curable. This is exciting news for men who experience a rise in PSA following primary or even secondary treatment whose cancer is still believed to be localized. While some are expressing concerns about toxicity of docetaxel and the robustness of the RTOG 0521 trial, we hope that this will spur larger clinical trials where earlier use of chemotherapy with hormone treatment is stringently studied. June 21, 2015.
The more emotionally distressed a man feels about his prostate cancer, the more likely he may be to choose more aggressive treatment even if he has lower-risk disease, according to a study (Orom et al) led by the University of Buffalo and Roswell Park Cancer Institute. Researchers assessed 1,050 men with clinically localized prostate cancer. Lack of confidence in deciding how to treat prostate cancer, fear that cancer would spread, and threat to masculinity were all factors that led to greater emotional distress. In a perfect world, physicians should factor in emotional distress when counseling patients and caregivers. The study has not yet been published, but results first appeared online in Psychooncology in the beginning of the year. June 13, 2015.
Nearly 7 in 10 men sometimes ignore their symptoms of prostate cancer, according to a recent Harris Poll survey that was commissioned by Bayer HealthCare and a partnership of prostate cancer patient support groups. More than 410 men with advanced prostate cancer and 95 caregivers revealed that 39% of men surveyed waited to tell their healthcare team about symptoms they were experiencing, even though more than half (52%) associated symptoms like pain with their prostate cancer getting worse. One in 5 men experienced pain for one year or longer prior to a diagnosis of advanced prostate cancer. Why don’t men speak up? One in 5 men (22%) reported they feel weak talking about their pain and 55% feel it’s just something they have to live with. Interestingly, caregivers had differing opinions on the impact of advanced prostate cancer on men’s lives. The most common advanced prostate cancer symptoms experienced by survey respondents with cancer that spread to their bones included fatigue, pain or aches in specific areas, general all-over-body pain or aches, numbness or weakness, difficulty sleeping as a result of pain, anxiety or distress as a result of pain, and difficulty doing normal activities. The symptoms of advanced prostate cancer are the focus of a new Men Who Speak Up educational initiative and website, which is designed to get men to speak to their doctors about treatment. June 11, 2015.
We know that a diet rich in fruits and vegetables can help prevent prostate cancer. Now researchers from Harvard T.H. Chan School of Public Health are reporting that men with prostate cancer who eat a Western diet high in red and processed meats, high-fat dairy foods, and refined grains had more than twice the risk of prostate cancer-related death. Researchers (Meng et al) followed 926 men with prostate cancer over an average of 14 years after their diagnosis. Men who ate prudently had a 36% lower risk of death from all causes. Eating prudently means making healthier choices, such as fresh fruit over cupcakes, steamed broccoli instead of French fries, broiled fish rather than grilled filet mignon, and whole-grain foods over sugary cereals. The results of study were published in the June 1 online journal Cancer Prevention Research. June 4, 2015.
The Department of Psychology at the University of Sheffield is conducting research into how partners’ psychological traits might impact on how people with cancer feel about themselves. You and your spouse/partner can participate as a pair, but you must complete a survey separately. The study involves filling out a series of short questionnaires and will take approximately 15 minutes. All responses are anonymous and will be treated confidentially. For every couple that participates, £1 will be donated to Worldwide Cancer Research. Learn more here (enter the password: sheffpsy). May 22, 2015.
Combing chemotherapy with immunotherapy (now called chemoimmunotherapy), achieved near complete remission in mouse models of advanced prostate cancer, according to researchers at the University of California, San Diego School of Medicine. The results of this study (Font-Burgada et al) were published in the April 29 edition of Nature. May 5, 2015.
A new study reports that men rarely regain normal sexual function after radical prostatectomy (RP). This was a small study of 210 men who completed a questionnaire nearly two years after surgery. Only 6.7% of men (14) reported having erectile function as good as it was before surgery. Why is this news coming just now? The researchers suggest that men were being asked the wrong question concerning erectile function. What we’d like to see is a much larger study of thousands of men that addresses this question at 2, 3, and 4 years years after surgery. We’d also like to know whether all of these men had traditional RP and used different surgeons. The results of the study were presented at the European Association of Urology Congress in Madrid (this was first reported by Science Daily). March 31, 2015.
Men who currently smoke, or have stopped smoking less than a decade ago, have twice the risk of prostate cancer recurrence following radical prostatectomy. This comes from new research presented at the European Association of Urology conference in Madrid, as reported by Medical News Today. Researchers in a retrospective study followed 7,191 men for an average of 28 months. About one third of men were smokers, another third never smoked, and another third were former smokers. Even those men who quit smoking in the last 10 years had a significantly higher risk of their cancer coming back. Another good reason to stomp out smoking! March 24, 2015.
We know that chemotherapy with docetaxel is effective in men with prostate cancer who no longer respond to hormone treatment. Now a newer member of the taxane family of chemotherapy drugs called cabazitaxel is showing promise, according to a new study published online in Clinical Cancer Research. Researchers found that cabazitaxel was more effective than docetaxel against hormone-resistant, human prostate cancer cell lines in laboratory studies. Testing in actual humans is needed. What we would love to see is a study about the effectiveness of chemotherapy as an early treatment for advanced prostate cancer before hormone therapy. The protocol has always been chemotherapy following hormone therapy failure. But could early chemotherapy following a PSA rise after surgery and/or radiation be more effective or even curative? February 21, 2015.
There is a growing body of evidence (see the abstracts of current studies in the link below) that MRI-guided prostate biopsies may be more accurate in detecting prostate cancer than traditional transrectal ultrasound biopsies. Unfortunately, no current method of detecting prostate cancer is 100% accurate. Talk to your doctor and your insurance company as MRI-guided biopsies may be more expensive. February 19, 2015.
Always consult a medical professional.